- Prescribing Advice for GPs - https://www.prescriber.org.uk -

SMC Update - July 2022

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Solriamfetol (Sunosi®) has been accepted for restricted use to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy). The restriction limits use to patients who have failed to respond to modafinil or have a contraindication or intolerance to modafinil.

Delafloxacin (Quofenix®) has been accepted for restricted use for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of this infection. The restrictions limits use to patients with suspected or confirmed polymicrobial infection following treatment failure or when standard antibacterial therapies are not suitable. It is also noted that delafloxacin should be used on the advice of local microbiologists or specialists in infectious disease.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.